The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
home / investigator-perspectives / the-phase-3-clear-trial-lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carc
Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.